These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15388420)

  • 1. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.
    Van Herrewege Y; Vanham G; Michiels J; Fransen K; Kestens L; Andries K; Janssen P; Lewi P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3684-9. PubMed ID: 15388420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission.
    Van Herrewege Y; Penne L; Vereecken C; Fransen K; van der Groen G; Kestens L; Balzarini J; Vanham G
    AIDS Res Hum Retroviruses; 2002 Oct; 18(15):1091-102. PubMed ID: 12396448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.
    Njai HF; Lewi PJ; Janssen CG; Garcia S; Fransen K; Kestens L; Vanham G; Janssen PA
    Antivir Ther; 2005; 10(2):255-62. PubMed ID: 15865220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.
    Van Herrewege Y; Michiels J; Van Roey J; Fransen K; Kestens L; Balzarini J; Lewi P; Vanham G; Janssen P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):337-9. PubMed ID: 14693562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anti-HIV activity of aryl-2-[(4-cyanophenyl)amino]-4-pyrimidinone hydrazones as potent non-nucleoside reverse transcriptase inhibitors.
    Ma XD; Yang SQ; Gu SX; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    ChemMedChem; 2011 Dec; 6(12):2225-32. PubMed ID: 21990112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
    Van Herrewege Y; Morellato L; Descours A; Aerts L; Michiels J; Heyndrickx L; Martin L; Vanham G
    J Antimicrob Chemother; 2008 Apr; 61(4):818-26. PubMed ID: 18270220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.
    Huang B; Kang D; Yang J; Zhan P; Liu X
    Expert Opin Ther Pat; 2016; 26(2):281-9. PubMed ID: 26559996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
    Gu SX; Yang SQ; He QQ; Ma XD; Chen FE; Dai HF; Clercq ED; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Dec; 19(23):7093-9. PubMed ID: 22037050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection.
    Terrazas-Aranda K; Van Herrewege Y; Lewi PJ; Van Roey J; Vanham G
    Antivir Chem Chemother; 2007; 18(3):141-51. PubMed ID: 17626598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides.
    Van Herrewege Y; Michiels J; Waeytens A; De Boeck G; Salden E; Heyndrickx L; van den Mooter G; de Béthune MP; Andries K; Lewi P; Praet M; Vanham G
    Antiviral Res; 2007 May; 74(2):111-24. PubMed ID: 17097156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
    Guillemont J; Pasquier E; Palandjian P; Vernier D; Gaurrand S; Lewi PJ; Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers MH; Arnold E; Das K; Pauwels R; Andries K; de Béthune MP; Bettens E; Hertogs K; Wigerinck P; Timmerman P; Janssen PA
    J Med Chem; 2005 Mar; 48(6):2072-9. PubMed ID: 15771449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission.
    Ariën KK; Venkatraj M; Michiels J; Joossens J; Vereecken K; Van der Veken P; Abdellati S; Cuylaerts V; Crucitti T; Heyndrickx L; Heeres J; Augustyns K; Lewi PJ; Vanham G
    J Antimicrob Chemother; 2013 Sep; 68(9):2038-47. PubMed ID: 23645585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-nucleoside reverse transcriptase inhibitors (Part 18): synthesis and anti-HIV activity of 4-allylamino or 4-azido substituted diaryltriazines.
    Xiong YZ; Hu HR; Chen FE; Balzarini J; Pannecouque C; de Clercq E
    Yao Xue Xue Bao; 2009 Feb; 44(2):145-9. PubMed ID: 19408683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.
    Terrazas-Aranda K; Van Herrewege Y; Hazuda D; Lewi P; Costi R; Di Santo R; Cara A; Vanham G
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2544-54. PubMed ID: 18474579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.
    Xiong YZ; Chen FE; Balzarini J; De Clercq E; Pannecouque C
    Eur J Med Chem; 2008 Jun; 43(6):1230-6. PubMed ID: 17869386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
    Gu SX; Li ZM; Ma XD; Yang SQ; He QQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Eur J Med Chem; 2012 Jul; 53():229-34. PubMed ID: 22575532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Liang YH; Feng XQ; Zeng ZS; Chen FE; Balzarini J; Pannecouque C; De Clercq E
    ChemMedChem; 2009 Sep; 4(9):1537-45. PubMed ID: 19591191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DABOs as candidates to prevent mucosal HIV transmission.
    Pani A; Musiu C; Loi AG; Mai A; Loddo R; La Colla P; Marongiu ME
    Antivir Chem Chemother; 2001; 12 Suppl 1():51-9. PubMed ID: 11594689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
    Gu SX; He QQ; Yang SQ; Ma XD; Chen FE; De Clercq E; Balzarini J; Pannecouque C
    Bioorg Med Chem; 2011 Sep; 19(17):5117-24. PubMed ID: 21824782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.